WASHINGTON -- Freedom from relapse was maintained in multiple sclerosis patients on natalizumab (Tysabri) who received the infusion drug less frequently than the recommended 4-week interval, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback